Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Karyopharm Therapeutics (KPTI) Accumulated Depreciation & Amortization (2016 - 2025)

Karyopharm Therapeutics' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 17.65% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $5.5 million, down 17.65%, while the annual FY2025 figure was $5.5 million, 17.65% down from the prior year.
  • Accumulated Depreciation & Amortization reached $5.5 million in Q4 2025 per KPTI's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.7 million in Q4 2024 to a low of $5.5 million in Q4 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $6.3 million, with a median of $6.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 16.75% in 2021, then fell 17.65% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $6.1 million in 2021, then grew by 9.71% to $6.6 million in 2022, then fell by 1.2% to $6.6 million in 2023, then increased by 1.92% to $6.7 million in 2024, then dropped by 17.65% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Accumulated Depreciation & Amortization are $5.5 million (Q4 2025), $6.7 million (Q4 2024), and $6.6 million (Q4 2023).